Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that data from a systematic literature review assessing the frequency of fetal and neonatal alloimmune thrombocytopenia (FNAIT) risk among pregnant mothers will be presented at the Academy of Managed Care Pharmacy (AMCP) 2024 Annual Meeting in New Orleans from April 15th to 18th.
- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that data from a systematic literature review assessing the frequency of fetal and neonatal alloimmune thrombocytopenia (FNAIT) risk among pregnant mothers will be presented at the Academy of Managed Care Pharmacy (AMCP) 2024 Annual Meeting in New Orleans from April 15th to 18th.
- Rallybio is developing RLYB212, a novel human monoclonal anti-HPA-1a antibody designed to prevent alloimmunization in at-risk pregnant mothers, thereby eliminating the risk of FNAIT and its potentially devastating consequences in fetuses and newborns.
- Details of the poster presentation are as follows:
Title: Fetal and Neonatal Alloimmune Thrombocytopenia: A Systematic Literature Review and Meta-analysis of Adverse Pregnancy-Related Outcomes to Support the Development of a Novel Prophylactic Therapeutic
Poster Session Date and Time: April 17, 2024, 1:00 - 2:30 p.m. CDT (2:00 - 3:30 p.m. EDT)
Additional information about the AMCP 2024 Annual Meeting is available at: https://amcpannual.org/